InfuSystem Holdings, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by InfuSystem Holdings, Inc. on March 14, 2013. The filing addresses significant changes in executive leadership and board composition effective April 1, 2013.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.
Material Changes
- Executive Departure: Dilip Singh will resign as Interim Chief Executive Officer effective April 1, 2013.
- New CEO Appointment: Eric K. Steen has been appointed Chief Executive Officer and a member of the Board of Directors, effective April 1, 2013.
- Board Expansion: The Board size has increased from seven to eight directors to accommodate Mr. Steen's appointment.
Compensation, Outlook, and Risks
The filing details the Employment Agreement and Inducement Stock Option Agreement for Mr. Steen:
- Base Salary: $300,000 for the initial one-year term.
- Performance Bonus: Eligible for an annual bonus up to 75% of base salary ($225,000), contingent on performance objectives.
- Stock Options: Granted 700,000 inducement stock options outside the 2007 Stock Option Plan.
- 300,000 options at an exercise price of $1.75.
- 400,000 options at an exercise price of $2.75.
- Vesting schedule: 25% on the first anniversary, with the remainder vesting pro rata monthly over the subsequent 36 months.
- Severance: In the event of involuntary termination without cause, Mr. Steen is entitled to six months of base salary plus accrued benefits, provided he executes a general release.
- Relocation: Reimbursement of reasonable expenses up to $20,000.
The filing does not contain specific forward-looking guidance, risk factors, or discussion of unusual items beyond the standard terms of the employment contract.
Investor Verification Checklist
- Verify the effective date of the leadership transition (April 1, 2013).
- Review the full text of the Employment Agreement (Exhibit 10.1) and Inducement Stock Option Agreement (Exhibit 10.2) for complete terms.
- Confirm the dilution impact of the 700,000 new stock options granted to the CEO.
- Assess Mr. Steen's prior experience at Central Admixture Pharmacy Services and B. Braun Medical Inc. as disclosed in the filing.